MISSISSAUGA, ON, May 2, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the first quarter of 2025 after the market close on Thursday, May 8, 2025. The Company will also hold a conference call on Friday, May 9, 2025 at 8:30am ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE: | Friday, May 9, 2025 |
TIME: | 8:30 a.m. ET |
DIAL-IN NUMBER: | 416-945-7677 or 888-699-1199 |
REPLAY: | 289-819-1450 or 888-660-6345 Code: 69080# |
Expires: May, 16, 2025 | |
WEBCAST: |
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.
| Last Trade: | C$15.65 |
| Daily Change: | -0.29 -1.82 |
| Daily Volume: | 41,263 |
| Market Cap: | C$397.230M |
August 07, 2025 May 08, 2025 April 29, 2025 November 07, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
